查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136912

全球排卵障碍诊断市场-2022-2029

Global Ovulation Disorder Diagnosis Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

排卵障碍诊断市场的增长是由计划怀孕增加、生育率下降以及公众对各种排卵障碍认识的提高推动的

2 型糖尿病患者多囊卵巢综合征 (PCOS) 的患病率预计将推动市场增长

多囊卵巢综合征 (PCOS) 是一种常见的代谢和内分泌生殖疾病，与心血管、代谢和心理因素有关，据说影响全球约 7% 的女性。我来了。根据 2022 年 8 月发表在内分泌学前沿的一篇论文，糖尿病 (DM) 是一个全球公共卫生问题。到 2021 年，全球约有 5.37 亿成年人（20-79 岁）将患有 DM，其中大多数是年轻人。现在越来越多的人在年轻时患上 2 型糖尿病（T2DM），而患有 T2DM 的女性在生育期更容易受到影响。 T2DM女性患者的生殖功能障碍正在谨慎增加。与非 T2DM 患者相比，T2DM 患者表现出更多的临床变化，如月经紊乱和多囊卵巢。这可能与促黄体激素和胰岛素协同作用引起的细胞内雄激素水平升高有关。

PCOS 还归因于 2 型糖尿病患者的内在胰岛素抵抗和高胰岛素血症，这会刺激卵巢颗粒细胞促进小卵泡的生长和数量。 PCOS 和 T2DM 具有生化、临床和代谢特征。 PCOS 和 T2DM 患者之间的重迭率也很高。涉及 PCOS 的 T2DM 可导致对生殖系统的评估性损伤。 PCOS患者数量越多，市场就越大。

缺乏公众意识会阻碍市场增长。

但是，医疗保健专业人员和患者之间的巨大知识差距是造成诊断延迟和治疗变化多端的原因。此外，缺乏可获取的循证信息让受影响的女性感到沮丧。许多女性不知道排卵，导致误诊、不孕和相关的健康风险。

COVID-19 影响分析

COVID-19 的出现对全球排卵障碍诊断市场产生了相当大的影响。根据 2020 年 7 月发表在 BMC Medicine 上的一篇论文，多囊卵巢综合征 (PCOS) 是育龄女性最常见的内分泌疾病，患病率为 10-15%。甚至可能更多。因此，他们更有可能感染 COVID-19。另一方面，在大流行期间，交通限制和封锁使许多患者难以接受常规治疗。大流行期间许多行业被封锁，这对市场产生了负面影响。

但是，在 2022 年年中而不是 2021 年，情况会有所改善，您将能够在医院接受治疗。预计该市场在预测期内也将显示出良好的增长。

全球排卵障碍诊断市场报告将提供对大约 65 多个市场数据表、65 多个图表和 200 多页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按排卵障碍划分的市场细分
  • 按诊断划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 肥胖率上升
      • 糖尿病患病率增加
    • 约束因素
      • 诊断识别率低
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章排卵障碍

  • 多囊卵巢综合征
  • 高催乳素血症
  • 黄体期衰竭
  • 下丘脑功能障碍
  • 肿瘤
  • 自身免疫性卵巢炎
  • 原发性卵巢功能不全
  • 抵抗性卵巢综合征
  • 其他

第8章诊断

  • 荷尔蒙实验室测试
  • 垂体和下丘脑的 CT 和 MRI 扫描
  • 卵巢活检
  • 其他

第 9 章，最终用户

  • 医院
  • 妇科诊所
  • 诊断中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 12 章公司简介

  • 西门子医疗保健
    • 公司简介
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • GE Healthcare
  • Fujifilm Holdings
  • Swiss Precision Diagnostics
  • Toshiba Medical Systems Corporation
  • Carestream Health
  • Genova Diagnostics
  • Quest Diagnostics
  • LabCorp
  • Esaote

第 13 章全球排卵障碍诊断市场-DataM

简介目录
Product Code: DMCD803

Market Overview

Ovulation Disorder Diagnosis Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.8% during the forecast period (2022-2029).

Ovulation disorders are the main source of infertility in women or girls. Ovulation disorders are disturbances in the production of an egg during a woman's menstrual cycle. The disorders often occur due to hypothalamic dysfunction, premature ovarian failure and polycystic ovary syndrome.

Market Dynamics

The ovulation disorder diagnosis market growth is driven by the rising adoption of planned pregnancies, a decrease in fertility rate along with increasing awareness of different ovulation disorders among the public

The prevalence of polycystic ovary syndrome (PCOS) in patients with type 2 diabetes is expected to drive the market growth

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10-15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Geographical Analysis

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio.

Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

  • In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)

Overview:

TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Ovulation Disorders
  • 3.2. Market Snippet By Diagnosis
  • 3.3. Market Snippet By End-users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising obesity rates
      • 4.1.1.2. The increasing prevalence of diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of diagnosis
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ovulation Disorders

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 7.1.2. Market Attractiveness Index, By Ovulation Disorders
  • 7.2. Polycystic Ovarian Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hyperprolactinemia
  • 7.4. Luteal Phase Defect
  • 7.5. Hypothalamus Dysfunction
  • 7.6. Tumors
  • 7.7. Autoimmune Oophoritis
  • 7.8. Primary Ovarian Failure
  • 7.9. Resistant Ovary Syndrome
  • 7.10. Others

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis
  • 8.2. Laboratory Testing of Hormones*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
  • 8.4. Ovarian Biopsy
  • 8.5. Others

9. By End-users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.1.2. Market Attractiveness Index, By End-users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Gynecological Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.4.6.
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Siemens Healthcare*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GE Healthcare
  • 12.3. Fujifilm Holdings
  • 12.4. Swiss Precision Diagnostics
  • 12.5. Toshiba Medical Systems Corporation
  • 12.6. Carestream Health
  • 12.7. Genova Diagnostics
  • 12.8. Quest Diagnostics
  • 12.9. LabCorp
  • 12.10. Esaote

LIST NOT EXHAUSTIVE

13. Global Ovulation Disorder Diagnosis Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us